Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
Popularity: unranked [?]
Related posts:
- Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
- Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder
- Targacept Starts Phase 2b Clinical Trial Of TC-5214 As Augmentation Treatment In Major Depressive Disorder
- Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression
- Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
Comments
No Responses to “Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder”